Water Tower Research Publishes Initiation of Coverage Report on Ainos, Inc., “Initiating Coverage: AI Nose for Better Point-of-Care Testing”

June 17, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Ainos, Inc. (NASDAQ: AIMD) titled, “Initiating Coverage: AI Nose for Better Point-of-Care Testing” The report can be accessed here.

Ainos is a diversified medtech and biopharma company, developing medical diagnostics for point-of-care testing (POCT) devices, an IFN-α therapeutic (VELDONA) for infectious and autoimmune diseases, and synthetic RNA (SRNA) technology for vaccines and rapid tests. The POCT platform focuses on Anios’ AI Nose technology, which enables portable, non-invasive, telehealth-friendly POCT diagnostics that detect volatile organic compounds (VOCs), with an AI-powered algorithm to identify infections and other health disorders. The lead AI Nose product in development is Ainos Flora for women’s health and detection of common STIs. Pipeline drug VELDONA has reached Phase 2/3 trials for multiple indications, with Ainos prioritizing oral warts in HIV+ patients and Sjogren’s syndrome for further development. In addition, Ainos is capitalizing on the growing animal health market by first commercializing a line of pet supplements in Taiwan and moving forward with a clinical study for cat FCGS.

About Water Tower Research 

Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.

Tags: Diseases, MedTech, Point of Care Testing, proprietary AI algorithm, synthetic RNA, Women’s Health